Search

Your search keyword '"Perales, Miguel-Angel"' showing total 2,562 results
Start Over Author "Perales, Miguel-Angel"
2,562 results on '"Perales, Miguel-Angel"'

3. Conventional and novel [18F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma

Author

Leithner, Doris, Flynn, Jessica R., Devlin, Sean M., Mauguen, Audrey, Fei, Teng, Zeng, Shang, Zheng, Junting, Imber, Brandon S., Hubbeling, Harper, Mayerhoefer, Marius E., Bedmutha, Akshay, Luttwak, Efrat, Corona, Magdalena, Dahi, Parastoo B., Luna de Abia, Alejandro, Landego, Ivan, Lin, Richard J., Palomba, M. Lia, Scordo, Michael, Park, Jae H., Tomas, Ana Alarcon, Salles, Gilles, Lafontaine, Daniel, Michaud, Laure, Shah, Gunjan L., Perales, Miguel-Angel, Shouval, Roni, and Schöder, Heiko

Published
2024
Full Text
View/download PDF

4. Altered microbial bile acid metabolism exacerbates T cell-driven inflammation during graft-versus-host disease

Author

Lindner, Sarah, Miltiadous, Oriana, Ramos, Ruben J. F., Paredes, Jenny, Kousa, Anastasia I., Dai, Anqi, Fei, Teng, Lauder, Emma, Frame, John, Waters, Nicholas R., Sadeghi, Keimya, Armijo, Gabriel K., Ghale, Romina, Victor, Kristen, Gipson, Brianna, Monette, Sebastien, Russo, Marco Vincenzo, Nguyen, Chi L., Slingerland, John, Taur, Ying, Markey, Kate A., Andrlova, Hana, Giralt, Sergio, Perales, Miguel-Angel, Reddy, Pavan, Peled, Jonathan U., Smith, Melody, Cross, Justin R., Burgos da Silva, Marina, Campbell, Clarissa, and van den Brink, Marcel R. M.

Published
2024
Full Text
View/download PDF

7. Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients.

Author

Mahmood, Syed S, Riedell, Peter A, Feldman, Stephanie, George, Gina, Sansoterra, Stephen A, Althaus, Thomas, Rehman, Mahin, Mead, Elena, Liu, Jennifer E, Devereux, Richard B, Weinsaft, Jonathan W, Kim, Jiwon, Balkan, Lauren, Barbar, Tarek, Lee Chuy, Katherine, Harchandani, Bhisham, Perales, Miguel-Angel, Geyer, Mark B, Park, Jae H, Palomba, M Lia, Shouval, Roni, Tomas, Ana A, Shah, Gunjan L, Yang, Eric H, Gaut, Daria L, Rothberg, Michael V, Horn, Evelyn M, Leonard, John P, Van Besien, Koen, Frigault, Matthew J, Chen, Zhengming, Mehrotra, Bhoomi, Neilan, Tomas G, and Steingart, Richard M

Abstract

Chimeric antigen receptor T-cell therapy (CAR-T) harnesses a patient's immune system to target cancer. There are sparse existing data characterizing death outcomes after CAR-T-related cardiotoxicity. This study examines the association between CAR-T-related severe cardiovascular events (SCE) and mortality.From a multi-centre registry of 202 patients receiving anti-CD19 CAR-T, covariates including standard baseline cardiovascular and cancer parameters and biomarkers were collected. Severe cardiovascular events were defined as a composite of heart failure, cardiogenic shock, or myocardial infarction. Thirty-three patients experienced SCE, and 108 patients died during a median follow-up of 297 (interquartile range 104-647) days. Those that did and did not die after CAR-T were similar in age, sex, and prior anthracycline use. Those who died had higher peak interleukin (IL)-6 and ferritin levels after CAR-T infusion, and those who experienced SCE had higher peak IL-6, C-reactive protein (CRP), ferritin, and troponin levels. The day-100 and 1-year Kaplan-Meier overall mortality estimates were 18% and 43%, respectively, while the non-relapse mortality (NRM) cumulative incidence rates were 3.5% and 6.7%, respectively. In a Cox model, SCE occurrence following CAR-T was independently associated with increased overall mortality risk [hazard ratio (HR) 2.8, 95% confidence interval (CI) 1.6-4.7] after adjusting for age, cancer type and burden, anthracycline use, cytokine release syndrome grade ≥ 2, pre-existing heart failure, hypertension, and African American ancestry; SCEs were independently associated with increased NRM (HR 3.5, 95% CI 1.4-8.8) after adjusting for cancer burden.Chimeric antigen receptor T-cell therapy recipients who experience SCE have higher overall mortality and NRM and higher peak levels of IL-6, CRP, ferritin, and troponin.

Published
2023

8. Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial.

Author

Shaw, Bronwen, Jimenez-Jimenez, Antonio, Burns, Linda, Logan, Brent, Khimani, Farhad, Shaffer, Brian, Shah, Nirav, Mussetter, Alisha, Tang, Xiao-Ying, McCarty, John, Alavi, Asif, Farhadfar, Nosha, Jamieson, Katarzyna, Hardy, Nancy, Choe, Hannah, Ambinder, Richard, Anasetti, Claudio, Perales, Miguel-Angel, Spellman, Stephen, Howard, Alan, Luznik, Leo, Norkin, Maxim, Pidala, Joseph, Ratanatharathorn, Voravit, Confer, Dennis, Devine, Steven, Horowitz, Mary, Bolaños-Meade, Javier, and Komanduri, Krishna

Subjects
HLA, Hematopoietic cell transplant, Mismatched unrelated donor, Post transplant cyclophosphamide, Humans, Bone Marrow, Follow-Up Studies, Prospective Studies, Cyclophosphamide, Graft vs Host Disease, Unrelated Donors, Recurrence
Abstract

The use of post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis has resulted in reductions in GVHD and improved outcomes in allogeneic hematopoietic cell transplantation (HCT) using HLA-mismatched related donors. We report the 3-year outcomes of the first multicenter prospective clinical trial using PTCy in the setting of mismatched unrelated donor (MMUD) bone marrow HCT. The study enrolled 80 patients, treated with either myeloablative conditioning (MAC; n = 40) or reduced-intensity conditioning (RIC; n = 40), with the primary endpoint of 1-year overall survival (OS). The median follow-up for this study was 34 months (range, 12 to 46 months) in the RIC group and 36 months (range, 18 to 49 months) in the MAC group. Three-year OS and nonrelapse mortality were 70% and 15%, respectively, in the RIC group and 62% and 10% in the MAC group. No GVHD was reported after 1 year. The incidence of relapse was 29% in the RIC group and 51% in the MAC group. OS did not differ based on HLA match grade (63% in the 7/8 strata and 71% in the 4 to 6/8 strata). These encouraging outcomes, which were sustained for 3 years post-HCT, support the continued exploration of MMUD HCT using a PTCy platform. Important future areas to address include relapse reduction and furthering our understanding of optimal donor selection based on HLA and non-HLA factors.

Published
2023

10. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis.

Author

Saliba, Rima, Alousi, Amin, Pidala, Joseph, Arora, Mukta, Spellman, Stephen, Hemmer, Michael, Wang, Tao, Abboud, Camille, Ahmed, Sairah, Antin, Joseph, Beitinjaneh, Amer, Buchbinder, David, Byrne, Michael, Cahn, Jean-Yves, Choe, Hannah, Hanna, Rabi, Hematti, Peiman, Kamble, Rammurti, Kitko, Carrie, Laughlin, Mary, Lekakis, Lazaros, MacMillan, Margaret, Martino, Rodrigo, Mehta, Parinda, Nishihori, Taiga, Patel, Sagar, Perales, Miguel-Angel, Rangarajan, Hemalatha, Ringdén, Olov, Rosenthal, Joseph, Savani, Bipin, Schultz, Kirk, Seo, Sachiko, Teshima, Takanori, van der Poel, Marjolein, Verdonck, Leo, Weisdorf, Daniel, Wirk, Baldeep, Yared, Jean, Schriber, Jeffrey, Champlin, Richard, and Ciurea, Stefan

Subjects
Graft-versus-host disease, Non-relapse mortality, Post-transplantation cyclophosphamide, Prophylaxis, Antilymphocyte Serum, Cyclophosphamide, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Male, Retrospective Studies
Abstract

Post-transplantation cyclophosphamide (PTCy) has been shown to effectively control graft-versus-host disease (GvHD) in haploidentical (Haplo) transplantations. In this retrospective registry study, we compared GvHD organ distribution, severity, and outcomes in patients with GvHD occurring after Haplo transplantation with PTCy GvHD prophylaxis (Haplo/PTCy) versus HLA-matched unrelated donor transplantation with conventional prophylaxis (MUD/conventional). We evaluated 2 cohorts: patients with grade 2 to 4 acute GvHD (aGvHD) including 264 and 1163 recipients of Haplo and MUD transplants; and patients with any chronic GvHD (cGvHD) including 206 and 1018 recipients of Haplo and MUD transplants, respectively. In comparison with MUD/conventional transplantation ± antithymocyte globulin (ATG), grade 3-4 aGvHD (28% versus 39%, P = .001), stage 3-4 lower gastrointestinal (GI) tract aGvHD (14% versus 21%, P = .01), and chronic GI GvHD (21% versus 31%, P = .006) were less common after Haplo/PTCy transplantation. In patients with grade 2-4 aGvHD, cGvHD rate after Haplo/PTCY was also lower (hazard ratio [HR] = .4, P < .001) in comparison with MUD/conventional transplantation without ATG in the nonmyeloablative conditioning setting. Irrespective of the use of ATG, non-relapse mortality rate was lower (HR = .6, P = .01) after Haplo/PTCy transplantation, except for transplants that were from a female donor into a male recipient. In patients with cGvHD, irrespective of ATG use, Haplo/PTCy transplantation had lower non-relapse mortality rates (HR = .6, P = .04). Mortality rate was higher (HR = 1.6, P = .03) during, but not after (HR = .9, P = .6) the first 6 months after cGvHD diagnosis. Our results suggest that PTCy-based GvHD prophylaxis mitigates the development of GI GvHD and may translate into lower GvHD-related non-relapse mortality rate.

Published
2022

11. Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant

Author

Jimenez, Antonio Jimenez, Komanduri, Krishna, Brown, Samantha, Wang, Trent, Pereira, Denise, Goodman, Mark, Beitinjaneh, Amer, Lekakis, Lazaros, Chinapen, Stephanie, Devlin, Sean, Ponce, Doris, Sauter, Craig, Perales, Miguel-Angel, and Shaffer, Brian C

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Clinical Research, Clinical Trials and Supportive Activities, Transplantation, Cancer, Prevention, Hematology, Good Health and Well Being, Antilymphocyte Serum, Cyclophosphamide, Graft vs Host Disease, Humans, Methotrexate, Prospective Studies, Tacrolimus, Unrelated Donors, Cardiovascular medicine and haematology
Abstract

A common method to prevent graft-versus-host disease after allogeneic hematopoietic cell transplantation (HCT) from an HLA-mismatched unrelated donor (MMUD) is tacrolimus, methotrexate, and antithymocyte globulin (ATG). The use of posttransplant cyclophosphamide (PTCy) showed promise in a prospective trial for MMUD HCT. We compared 1-year graft-versus-host disease-free, relapse-free survival (GRFS) in 128 recipients of prophylaxis based on tacrolimus/methotrexate/ATG (ATG group, n = 46) vs PTCy, mycophenolate mofetil, and tacrolimus or sirolimus (PTCy group, n = 82) after MMUD HCT. Patients receiving HCT from a MMUD mismatched at ≥1 locus among HLA-A, HLA-B, HLA-C, and HLA-DRB1 were included. The 2 groups were well matched for HCT indication, high-risk disease, and HCT comorbidity index, whereas more patients on PTCy received bone marrow (50% vs 26%; P = .01) and >1 locus HLA-mismatched (30.5% vs 2.2%; P = .001) grafts. The 1-year GRFS was 16% (95% confidence interval (CI): 8%-31%) vs 54% (95% CI: 44%-66%; P < .001) in the ATG and PTCy groups, respectively. The multivariable adjusted hazard ratio for GRFS was 0.34 (95% CI: 0.21-0.55; P < .001) with the use of PTCy. The 1-year overall survival in the ATG group was 45% (95% CI: 32%-62%) vs 75% (95% CI: 66%-85%) in the PTCy group (P < .001). Relapse incidence was similar. One-year nonrelapse mortality was greater after ATG-based prophylaxis: 38% (95% CI: 23%-52%) vs 16% (95 CI: 9%-25%), P < .001. In summary, PTCy-based prophylaxis resulted in superior GRFS and overall survival in recipients of MMUD.

Published
2022

12. Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study

Author

Jain, Tania, Estrada-Merly, Noel, Salas, M. Queralt, Kim, Soyoung, DeVos, Jakob, Chen, Min, Fang, Xi, Kumar, Rajat, Andrade-Campos, Marcio, Elmariah, Hany, Agrawal, Vaibhav, Aljurf, Mahmoud, Bacher, Ulrike, Badar, Talha, Badawy, Sherif M., Ballen, Karen, Beitinjaneh, Amer, Bhatt, Vijaya Raj, Bredeson, Christopher, DeFilipp, Zachariah, Dholaria, Bhagirathbhai, Farhadfar, Nosha, Farhan, Shatha, Gandhi, Arpita P., Ganguly, Siddhartha, Gergis, Usama, Grunwald, Michael R., Hamad, Nada, Hamilton, Betty K., Inamoto, Yoshihiro, Iqbal, Madiha, Jamy, Omer, Juckett, Mark, Kharfan-Dabaja, Mohamed A., Krem, Maxwell M., Lad, Deepesh P., Liesveld, Jane, Al Malki, Monzr M., Malone, Adriana K., Murthy, Hemant S., Ortí, Guillermo, Patel, Sagar S., Pawarode, Attaphol, Perales, Miguel-Angel, van der Poel, Marjolein, Ringden, Olle, Rizzieri, David A., Rovó, Alicia, Savani, Bipin N., Savoie, Mary Lynn, Seo, Sachiko, Solh, Melhem, Ustun, Celalettin, Verdonck, Leo F., Wingard, John R., Wirk, Baldeep, Bejanyan, Nelli, Jones, Richard J., Nishihori, Taiga, Oran, Betul, Nakamura, Ryotaro, Scott, Bart, Saber, Wael, and Gupta, Vikas

Published
2024
Full Text
View/download PDF

14. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results

Author

Park, Jae H., Nath, Karthik, Devlin, Sean M., Sauter, Craig S., Palomba, M. Lia, Shah, Gunjan, Dahi, Parastoo, Lin, Richard J., Scordo, Michael, Perales, Miguel-Angel, Shouval, Roni, Tomas, Ana Alarcon, Cathcart, Elizabeth, Mead, Elena, Santomasso, Bianca, Holodny, Andrei, Brentjens, Renier J., Riviere, Isabelle, and Sadelain, Michel

Published
2023
Full Text
View/download PDF

15. Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Author

Locke, Frederick L., Siddiqi, Tanya, Jacobson, Caron A., Ghobadi, Armin, Ahmed, Sairah, Miklos, David B., Perales, Miguel-Angel, Munoz, Javier, Fingrut, Warren B., Pennisi, Martina, Gauthier, Jordan, Shadman, Mazyar, Gowda, Lohith, Mirza, Abu-Sayeef, Abid, Muhammad Bilal, Hong, Sanghee, Majhail, Navneet S., Kharfan-Dabaja, Mohamed A., Khurana, Arushi, Badar, Talha, Lin, Yi, Bennani, N. Nora, Herr, Megan M., Hu, Zhen-Huan, Wang, Hai-Lin, Baer, Anjani, Baro, Elande, Miao, Harry, Spooner, Clare, Xu, Hairong, and Pasquini, Marcelo C.

Published
2024
Full Text
View/download PDF

19. Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing

Author

Ptashkin, Ryan N., Ewalt, Mark D., Jayakumaran, Gowtham, Kiecka, Iwona, Bowman, Anita S., Yao, JinJuan, Casanova, Jacklyn, Lin, Yun-Te David, Petrova-Drus, Kseniya, Mohanty, Abhinita S., Bacares, Ruben, Benhamida, Jamal, Rana, Satshil, Razumova, Anna, Vanderbilt, Chad, Balakrishnan Rema, Anoop, Rijo, Ivelise, Son-Garcia, Julie, de Bruijn, Ino, Zhu, Menglei, Lachhander, Sean, Wang, Wei, Haque, Mohammad S., Seshan, Venkatraman E., Wang, Jiajing, Liu, Ying, Nafa, Khedoudja, Borsu, Laetitia, Zhang, Yanming, Aypar, Umut, Suehnholz, Sarah P., Chakravarty, Debyani, Park, Jae H., Abdel-Wahab, Omar, Mato, Anthony R., Xiao, Wenbin, Roshal, Mikhail, Yabe, Mariko, Batlevi, Connie Lee, Giralt, Sergio, Salles, Gilles, Rampal, Raajit, Tallman, Martin, Stein, Eytan M., Younes, Anas, Levine, Ross L., Perales, Miguel-Angel, van den Brink, Marcel R. M., Dogan, Ahmet, Ladanyi, Marc, Berger, Michael F., Brannon, A. Rose, Benayed, Ryma, Zehir, Ahmet, and Arcila, Maria E.

Published
2023
Full Text
View/download PDF

20. Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome

Author

Singh, Anurag, Dandoy, Christopher E, Chen, Min, Kim, Soyoung, Mulroney, Carolyn M, Kharfan-Dabaja, Mohamed A, Ganguly, Siddhartha, Maziarz, Richard T, Kanakry, Christopher G, Kanakry, Jennifer A, Patel, Sagar S, Hill, Joshua A, De Oliveir, Satiro, Taplitz, Randy, Hematti, Peiman, Lazarus, Hillard M, Abid, Muhammad Bilal, Goldsmith, Scott R, Romee, Rizwan, Komanduri, Krishna V, Badawy, Sherif M, Friend, Brian D, Beitinjaneh, Amer, Politikos, Ioannis, Perales, Miguel-Angel, and Riches, Marcie

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Rare Diseases, Cancer, Clinical Research, Stem Cell Research - Nonembryonic - Human, Hematology, Stem Cell Research, Transplantation, Infectious Diseases, Infection, Inflammatory and immune system, Good Health and Well Being, Cyclophosphamide, Cytomegalovirus Infections, Herpesviridae, Humans, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Prospective Studies, Non-CMV herpesvirus, Post-transplantation, cyclophosphamide, Haploidentical, Epstein-Barr virus, HHV-6, Post-transplantation cyclophosphamide, Clinical Sciences, Cardiovascular medicine and haematology
Abstract

The use of post-transplantation cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis in recipients of haploidentical and fully matched transplantations is on the increase. Published studies have reported an increased incidence of cytomegalovirus (CMV) infection with the use of PTCy. Limited data exist on the incidence and outcomes of infection with non-CMV herpesviruses (NCHV) in this setting. The aim of this study was to evaluate the cumulative incidence of NCHV infections and the association of NCHV infections with transplantation-specific outcomes in recipients of haploidentical transplantation with PTCy (HaploCy), matched sibling donor transplantation with PTCy (SibCy), and matched sibling donor transplantation with calcineurin inhibitor-based prophylaxis (SibCNI). We hypothesized that, like CMV infection, HaploCy recipients of also will have a higher risk of NCHV infections. Using the Center for International Blood and Marrow Transplantation Research database, we analyzed 2765 patients (HaploCy, n = 757; SibCNI, n = 1605; SibCy, n = 403) who had undergone their first hematopoietic stem cell transplantation (HCT) between 2012 and 2017 for acute myelogenous leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. The cumulative incidence of NCHV at 6 months post-NCT was 13.9% (99% confidence interval], 10.8% to 17.3%) in the HaploCy group, 10.7% (99% CI, 7.1% to 15%) in the SibCy group, and 5.7% (99% CI, 4.3% to 7.3%) in the Sib CNI group (P < .001). This was due primarily to a higher frequency of human herpesvirus 6 viremia reported in patients receiving PTCy. The incidence of Epstein-Barr viremia was low in all groups, and no cases of post-transplantation lymphoproliferative disorder were seen in either PTCy group. The incidence of NCHV organ disease was low in all 3 cohorts. The development of NCHV infection was associated with increased treatment-related mortality, particularly in the HaploCy group. There was no association with the development of GVHD, relapse, or disease-free survival. Patients in PTCy cohorts who did not develop NCHV infection had lower rates of cGVHD. This study demonstrates that the use of PTCy is associated with an increased risk of NCHV infection. The development of NCHV infection was associated with increased nonrelapse mortality, especially in the HaploCy group. Prospective trials should consider viral surveillance strategies in conjunction with assessment of immune reconstitution for a better understanding of the clinical relevance of viral reactivation in different HCT settings.

Published
2022

22. The incidence and impact of clostridioides difficile infection on transplant outcomes in acute leukemia and MDS after allogeneic hematopoietic cell transplant—a CIBMTR study

Author

Ramanathan, Muthalagu, Kim, Soyoung, He, Naya, Chen, Min, Hematti, Peiman, Abid, Muhammad Bilal, Rotz, Seth J., Williams, Kirsten M., Lazarus, Hillard M., Wirk, Baldeep, Yin, Dwight E., Kanakry, Christopher G., Perales, Miguel-Angel, Chemaly, Roy F., Dandoy, Christopher E., Riches, Marcie, and Ustun, Celalettin

Published
2023
Full Text
View/download PDF

23. A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia

Author

Metheny, Leland L., Sobecks, Ronald, Cho, Christina, Fu, Pingfu, Margevicius, Seunghee, Wang, Jiasheng, Ciarrone, Lisa, Kopp, Shelby, Convents, Robin D., Majhail, Navneet, Caimi, Paolo F., Otegbeye, Folashade, Cooper, Brenda W., Gallogly, Molly, Malek, Ehsan, Tomlinson, Benjamin, Gerds, Aaron T., Hamilton, Betty, Giralt, Sergio, Perales, Miguel-Angel, and de Lima, Marcos

Published
2024
Full Text
View/download PDF

24. Artificial intelligence enabled interpretation of ECG images to predict hematopoietic cell transplantation toxicity

Author

Shaffer, Brian C., Brown, Samantha, Chinapen, Stephanie, Mangold, Kathryn E., Lahoud, Oscar, Lopez-Jimenez, Francisco, Schaffer, Wendy, Liu, Jennifer, Giralt, Sergio, Devlin, Sean, Shah, Gunjan, Scordo, Michael, Papadopoulos, Esperanza, Landau, Heather, Usmani, Saad, Perales, Miguel-Angel, Friedman, Paul A., Gersh, Bernard J., Attia, Itzhak Zachi, Noseworthy, Peter A., and Kosmidou, Ioanna

Published
2024
Full Text
View/download PDF

26. Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma

Author

Lorenc, Rachel, Shouval, Roni, Flynn, Jessica R., Devlin, Sean M., Saldia, Amethyst, De Abia, Alejandro Luna, De Lapuerta, Magdalena Corona, Tomas, Ana Alarcon, Cassanello, Giulio, Leslie, Lori A., Rejeski, Kai, Lin, Richard J., Scordo, Michael, Shah, Gunjan L., Palomba, M. Lia, Salles, Gilles, Park, Jae, Giralt, Sergio A., Perales, Miguel-Angel, Ip, Andrew, and Dahi, Parastoo B.

Published
2024
Full Text
View/download PDF

27. CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas

Author

Cederquist, Gustav Y., Schefflein, Javin, Devlin, Sean M., Shah, Gunjan L., Shouval, Roni, Hubbeling, Harper, Tringale, Kathryn, Alarcon Tomas, Ana, Fregonese, Beatrice, Hajj, Carla, Boardman, Alexander, Luna De Abia, Alejandro, Corona, Magdalena, Cassanello, Giulio, Dahi, Parastoo B., Lin, Richard J., Ghione, Paola, Salles, Gilles, Perales, Miguel-Angel, Palomba, M. Lia, Falchi, Lorenzo, Scordo, Michael, Grommes, Christian, Yahalom, Joachim, and Imber, Brandon S.

Published
2024
Full Text
View/download PDF

29. Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Author

Nath, Karthik, Peterson, Kristen, Brown, Samantha, Devlin, Sean, Rodriguez, Natasia, Barker, Juliet, Giralt, Sergio, Gyurkocza, Boglarka, Jakubowski, Ann, Papadopoulos, Esperanza, Ponce, Doris, Scordo, Michael, Shah, Gunjan, Perales, Miguel-Angel, Sauter, Craig, Lin, Andrew, and Dahi, Parastoo B.

Published
2024
Full Text
View/download PDF

30. Incidence and impact of community respiratory viral infections in post‐transplant cyclophosphamide‐based graft‐versus‐host disease prophylaxis and haploidentical stem cell transplantation

Author

Mulroney, Carolyn M, Abid, Muhammad Bilal, Bashey, Asad, Chemaly, Roy F, Ciurea, Stefan O, Chen, Min, Dandoy, Christopher E, Perez, Miguel A Diaz, Friend, Brian D, Fuchs, Ephraim, Ganguly, Siddhartha, Goldsmith, Scott R, Kanakry, Christopher G, Kim, Soyoung, Komanduri, Krishna V, Krem, Maxwell M, Lazarus, Hillard M, Ljungman, Per, Maziarz, Richard, Nishihori, Taiga, Patel, Sagar S, Perales, Miguel‐Angel, Romee, Rizwan, Singh, Anurag K, Wingard, John Reid, Yared, Jean, Riches, Marcie, and Taplitz, Randy

Subjects
Prevention, Transplantation, Lung, Stem Cell Research - Nonembryonic - Human, Stem Cell Research, Hematology, Rare Diseases, Organ Transplantation, Orphan Drug, Cancer, Infection, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Community-Acquired Infections, Cyclophosphamide, Female, Graft vs Host Disease, HLA Antigens, Hematopoietic Stem Cell Transplantation, Humans, Immunosuppressive Agents, Incidence, Kaplan-Meier Estimate, Leukemia, Living Donors, Male, Middle Aged, Myelodysplastic Syndromes, Proportional Hazards Models, Respiratory Tract Infections, Retrospective Studies, Siblings, Transplantation, Haploidentical, Virus Diseases, Young Adult, Respiratory viral infection, Post Transplant Cyclophosphamide, Allogeneic transplant, Cardiorespiratory Medicine and Haematology, Immunology
Abstract

Community respiratory viral infections (CRVIs) are associated with pulmonary function impairment, alloimmune lung syndromes and inferior survival in human leucocyte antigen (HLA)-matched allogeneic haematopoietic stem cell transplant (HCT) recipients. Although the incidence of viral infections in HLA-haploidentical HCT recipients who receive post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis is reportedly increased, there are insufficient data describing the incidence of CRVIs and the impact of donor source and PTCy on transplant outcomes. Analysing patients receiving their first HCT between 2012 and 2017 for acute myeloid leukaemia, acute lymphoblastic leukaemia and myelodysplastic syndromes, we describe comparative outcomes between matched sibling transplants receiving either calcineurin-based GVHD prophylaxis (SibCNI, N = 1605) or PTCy (SibCy, N = 403), and related haploidentical transplants receiving PTCy (HaploCy, N = 757). The incidence of CRVIs was higher for patients receiving PTCy, regardless of donor type. Patients in the HaploCy cohort who developed a CRVI by day +180 had both a higher risk of treatment-related mortality [hazard ratio (HR) 2⋅14, 99% confidence interval (CI) 1⋅13-4⋅07; P = 0⋅002] and inferior 2-year overall survival (HR 1⋅65, 99% CI 1⋅11-2⋅43; P = 0⋅001) compared to SibCNI with no CRVI. This finding justifies further research into long-term antiviral immune recovery, as well as development of preventive and treatment strategies to improve long-term outcomes in such patients.

Published
2021

31. Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma

Author

Alarcon Tomas, Ana, Fein, Joshua A., Fried, Shalev, Flynn, Jessica R., Devlin, Sean M., Fingrut, Warren B., Anagnostou, Theodora, Alperovich, Anna, Shah, Nishi, Fraint, Ellen, Lin, Richard J., Scordo, Michael, Batlevi, Connie Lee, Besser, Michal J., Dahi, Parastoo B., Danylesko, Ivetta, Giralt, Sergio, Imber, Brandon S., Jacoby, Elad, Kedmi, Meirav, Nagler, Arnon, Palomba, M. Lia, Roshal, Mikhail, Salles, Gilles A., Sauter, Craig, Shem-Tov, Noga, Shimoni, Avichai, Yahalom, Joachim, Yerushalmi, Ronit, Shah, Gunjan L., Avigdor, Abraham, Perales, Miguel-Angel, and Shouval, Roni

Published
2023
Full Text
View/download PDF

32. National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide

Author

Shaw, Bronwen E, Jimenez-Jimenez, Antonio Martin, Burns, Linda J, Logan, Brent R, Khimani, Farhad, Shaffer, Brian C, Shah, Nirav N, Mussetter, Alisha, Tang, Xiao-Ying, McCarty, John M, Alavi, Asif, Farhadfar, Nosha, Jamieson, Katarzyna, Hardy, Nancy M, Choe, Hannah, Ambinder, Richard F, Anasetti, Claudio, Perales, Miguel-Angel, Spellman, Stephen R, Howard, Alan, Komanduri, Krishna V, Luznik, Leo, Norkin, Maxim, Pidala, Joseph A, Ratanatharathorn, Voravit, Confer, Dennis L, Devine, Steven M, Horowitz, Mary M, and Bolaños-Meade, Javier

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Immunology, Transplantation, Clinical Trials and Supportive Activities, Hematology, Rare Diseases, Clinical Research, Regenerative Medicine, Good Health and Well Being, Adolescent, Adult, Aged, Cyclophosphamide, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Lymphoma, Male, Medically Underserved Area, Middle Aged, Minority Groups, Myelodysplastic Syndromes, Prospective Studies, Registries, Transplantation Conditioning, Unrelated Donors, Young Adult, Oncology and Carcinogenesis, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeHematopoietic cell transplantation (HCT) is curative for hematologic disorders, but outcomes are historically inferior when using HLA-mismatched donors. Despite unrelated donor registries listing > 38 million volunteers, 25%-80% of US patients lack an HLA-matched unrelated donor, with significant disparity across ethnic groups. We hypothesized that HCT with a mismatched unrelated donor (MMUD) using post-transplant cyclophosphamide (PTCy), a novel strategy successful in overcoming genetic disparity using mismatched related donors, would be feasible and increase access to HCT.Patients and methodsWe performed a prospective phase II study of MMUD bone marrow HCT with PTCy for patients with hematologic malignancies. The primary end point was 1-year overall survival (OS), hypothesized to be 65% or better. 80 patients enrolled at 11 US transplant centers (December 2016-March 2019). Following myeloablative or reduced-intensity conditioning-based HCT, patients received PTCy on days +3, +4, with sirolimus and mycophenolate mofetil starting on day +5. We compared outcomes to Center for International Blood and Marrow Transplant Research contemporary controls receiving PTCy.ResultsNotably, 48% of patients enrolled were ethnic minorities. 39% of pairs were matched for 4-6 out of 8 HLA alleles. The primary end point was met, with 1-year OS of 76% (90% CI, 67.3 to 83.3) in the entire cohort, and 72% and 79% in the myeloablative and reduced-intensity conditioning strata, respectively. Secondary end points related to engraftment and graft-versus-host-disease were reached. Multivariate analysis comparing the study group with other mismatched HCT controls found no significant differences in OS.ConclusionOur prospective study demonstrates the feasibility and effectiveness of HCT with an MMUD in the setting of PTCy. Remarkably, nearly half of the study participants belonged to an ethnic minority population, suggesting this approach may significantly expand access to HCT.

Published
2021

37. Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

Author

Scordo, Michael, Flynn, Jessica R., Gonen, Mithat, Devlin, Sean M., Parascondola, Allison, Tomas, Ana Alarcon, Shouval, Roni, Brower, Jamie, Porter, David L., Schuster, Stephen J., Bachanova, Veronika, Maakaron, Joseph, Maziarz, Richard T., Chen, Andy I., Nastoupil, Loretta J., McGuirk, Joseph P., Oluwole, Olalekan O., Ip, Andrew, Leslie, Lori A., Bishop, Michael R., Riedell, Peter A., and Perales, Miguel-Angel

Published
2023
Full Text
View/download PDF

38. Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation

Author

Tamari, Roni, Scordo, Michael, Kunvarjee, Binni M., Proli, Anthony, Lin, Andrew, Flynn, Jessica, Cho, Christina, Devlin, Sean, Klein, Elizabeth, Boulad, Farid, Cancio, Maria I., Curran, Kevin J., Jakubowski, Ann A., Kernan, Nancy A., Kung, Andrew L., O’Reilly, Richard J., Papadopoulos, Esperanza B., Prockop, Susan, Scaradavou, Andromachi, Shaffer, Brian C., Shah, Gunjan, Spitzer, Barbara, Gyurkocza, Boglarka, Giralt, Sergio A., Perales, Miguel-Angel, and Boelens, Jaap Jan

Published
2023
Full Text
View/download PDF

40. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma

Author

Epperla, Narendranath, Kumar, Ambuj, Abutalib, Syed A., Awan, Farrukh T., Chen, Yi-Bin, Gopal, Ajay K., Holter-Chakrabarty, Jennifer, Kekre, Natasha, Lee, Catherine J., Lekakis, Lazaros, Lin, Yi, Mei, Matthew, Nathan, Sunita, Nastoupil, Loretta, Oluwole, Olalekan, Phillips, Adrienne A., Reid, Erin, Rezvani, Andrew R., Trotman, Judith, Zurko, Joanna, Kharfan-Dabaja, Mohamed A., Sauter, Craig S., Perales, Miguel-Angel, Locke, Frederick L., Carpenter, Paul A., and Hamadani, Mehdi

Published
2023
Full Text
View/download PDF

41. Analysis of disparities in time to allogeneic transplantation in adults with acute myelogenous leukemia

Author

Fingrut, Warren B., Gyurkocza, Boglarka, Flynn, Jessica, Davis, Eric, Devlin, Sean, Scaradavou, Andromachi, Chinapen, Stephanie, Quach, Sean, Cho, Christina, Giralt, Sergio A., Jakubowski, Ann A., Lin, Richard J., Papadopoulos, Esperanza B., Perales, Miguel-Angel, Ponce, Doris, Shaffer, Brian C., Tamari, Roni, Young, James W., Politikos, Ioannis, and Barker, Juliet N.

Published
2023
Full Text
View/download PDF

42. The TaxUMAP atlas: Efficient display of large clinical microbiome data reveals ecological competition in protection against bacteremia

Author

Schluter, Jonas, Djukovic, Ana, Taylor, Bradford P., Yan, Jinyuan, Duan, Caichen, Hussey, Grant A., Liao, Chen, Sharma, Sneh, Fontana, Emily, Amoretti, Luigi A., Wright, Roberta J., Dai, Anqi, Peled, Jonathan U., Taur, Ying, Perales, Miguel-Angel, Siranosian, Benjamin A., Bhatt, Ami S., van den Brink, Marcel R.M., Pamer, Eric G., and Xavier, Joao B.

Published
2023
Full Text
View/download PDF

44. Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Author

Smith, Melody, Dai, Anqi, Ghilardi, Guido, Amelsberg, Kimberly V., Devlin, Sean M., Pajarillo, Raymone, Slingerland, John B., Beghi, Silvia, Herrera, Pamela S., Giardina, Paul, Clurman, Annelie, Dwomoh, Emmanuel, Armijo, Gabriel, Gomes, Antonio L. C., Littmann, Eric R., Schluter, Jonas, Fontana, Emily, Taur, Ying, Park, Jae H., Palomba, Maria Lia, Halton, Elizabeth, Ruiz, Josel, Jain, Tania, Pennisi, Martina, Afuye, Aishat Olaide, Perales, Miguel-Angel, Freyer, Craig W., Garfall, Alfred, Gier, Shannon, Nasta, Sunita, Landsburg, Daniel, Gerson, James, Svoboda, Jakub, Cross, Justin, Chong, Elise A., Giralt, Sergio, Gill, Saar I., Riviere, Isabelle, Porter, David L., Schuster, Stephen J., Sadelain, Michel, Frey, Noelle, Brentjens, Renier J., June, Carl H., Pamer, Eric G., Peled, Jonathan U., Facciabene, Andrea, van den Brink, Marcel R. M., and Ruella, Marco

Published
2023
Full Text
View/download PDF

46. High-resolution analyses of associations between medications, microbiome, and mortality in cancer patients

Author

Nguyen, Chi L., Markey, Kate A., Miltiadous, Oriana, Dai, Anqi, Waters, Nicholas, Sadeghi, Keimya, Fei, Teng, Shouval, Roni, Taylor, Bradford P., Liao, Chen, Slingerland, John B., Slingerland, Ann E., Clurman, Annelie G., Maloy, Molly A., Bohannon, Lauren, Giardina, Paul A., Brereton, Daniel G., Armijo, Gabriel K., Fontana, Emily, Gradissimo, Ana, Gyurkocza, Boglarka, Sung, Anthony D., Chao, Nelson J., Devlin, Sean M., Taur, Ying, Giralt, Sergio A., Perales, Miguel-Angel, Xavier, Joao B., Pamer, Eric G., Peled, Jonathan U., Gomes, Antonio L.C., and van den Brink, Marcel R.M.

Published
2023
Full Text
View/download PDF

47. SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study

Author

Hill, Joshua A., Martens, Michael J., Young, Jo-Anne H., Bhavsar, Kavita, Kou, Jianqun, Chen, Min, Lee, Lik Wee, Baluch, Aliyah, Dhodapkar, Madhav V., Nakamura, Ryotaro, Peyton, Kristin, Shahid, Zainab, Armistead, Paul, Westervelt, Peter, McCarty, John, McGuirk, Joseph, Hamadani, Mehdi, DeWolf, Susan, Hosszu, Kinga, Sharon, Elad, Spahn, Ashley, Toor, Amir A., Waldvogel, Stephanie, Greenberger, Lee M., Auletta, Jeffery J., Horowitz, Mary M., Riches, Marcie L., and Perales, Miguel-Angel

Published
2023
Full Text
View/download PDF

49. Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies

Author

Nikiforow, Sarah, Frigault, Matthew J., Frey, Noelle V., Gardner, Rebecca A., Komanduri, Krishna V., Perales, Miguel-Angel, Kebriaei, Partow, Warkentin, Phyllis Irene, Pasquini, Marcelo, Aho, Joy Lynn, Levine, Bruce L., Heslop, Helen E., Hlucky, Tracey L., Habucky, Karen, Gharibo, Mecide, Jagasia, Madan, and Locke, Frederick L.

Published
2023
Full Text
View/download PDF

50. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents.

Author

Roeker, Lindsey, Dreger, Peter, Brown, Jennifer, Lahoud, Oscar, Eyre, Toby, Brander, Danielle, Skarbnik, Alan, Coombs, Catherine, Kim, Haesook, Davids, Matthew, Manchini, Steven, George, Gemlyn, Shah, Nirav, Voorhees, Timothy, Orchard, Kim, Walter, Harriet, Arumainathan, Arvind, Sitlinger, Andrea, Park, Jae, Geyer, Mark, Zelenetz, Andrew, Sauter, Craig, Giralt, Sergio, Perales, Miguel-Angel, and Mato, Anthony

Subjects
Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Follicular, Retrospective Studies
Abstract

Although novel agents (NAs) have improved outcomes for patients with chronic lymphocytic leukemia (CLL), a subset will progress through all available NAs. Understanding outcomes for potentially curative modalities including allogeneic hematopoietic stem cell transplantation (alloHCT) following NA therapy is critical while devising treatment sequences aimed at long-term disease control. In this multicenter, retrospective cohort study, we examined 65 patients with CLL who underwent alloHCT following exposure to ≥1 NA, including baseline disease and transplant characteristics, treatment preceding alloHCT, transplant outcomes, treatment following alloHCT, and survival outcomes. Univariable and multivariable analyses evaluated associations between pre-alloHCT factors and progression-free survival (PFS). Twenty-four-month PFS, overall survival (OS), nonrelapse mortality, and relapse incidence were 63%, 81%, 13%, and 27% among patients transplanted for CLL. Day +100 cumulative incidence of grade III-IV acute graft-vs-host disease (GVHD) was 24%; moderate-severe GVHD developed in 27%. Poor-risk disease characteristics, prior NA exposure, complete vs partial remission, and transplant characteristics were not independently associated with PFS. Hematopoietic cell transplantation-specific comorbidity index independently predicts PFS. PFS and OS were not impacted by having received NAs vs both NAs and chemoimmunotherapy, 1 vs ≥2 NAs, or ibrutinib vs venetoclax as the line of therapy immediately pre-alloHCT. AlloHCT remains a viable long-term disease control strategy that overcomes adverse CLL characteristics. Prior NAs do not appear to impact the safety of alloHCT, and survival outcomes are similar regardless of number of NAs received, prior chemoimmunotherapy exposure, or NA immediately preceding alloHCT. Decisions about proceeding to alloHCT should consider comorbidities and anticipated response to remaining therapeutic options.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results